Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases.
Yu S, Li S, Henke A, Muse ED, Cheng B, Welzel G, Chatterjee AK, Wang D, Roland J, Glass CK, Tremblay M.
Yu S, et al. Among authors: li s.
FASEB J. 2016 Jul;30(7):2570-9. doi: 10.1096/fj.201600244R. Epub 2016 Mar 29.
FASEB J. 2016.
PMID: 27025962
Free PMC article.
Overall, these results provide evidence for the development of sterol-based LXR agonists as novel therapeutics for chronic inflammatory diseases.-Yu, S., Li, S., Henke, A., Muse, E. D., Cheng, B., Welzel, G., Chatterjee, A. K., Wang, D., Roland, J., Glass, C. …
Overall, these results provide evidence for the development of sterol-based LXR agonists as novel therapeutics for chronic inflammatory dise …